Decoding Immune Evasion in Cancer: Mechanisms, Therapeutic Strategies, and Future Directions

Mechanisms of Immune Evasion in Cancer

Cancer cells employ multiple mechanisms to evade immune surveillance, which can be broadly categorized as follows: (1) tumor-mediated immunosuppression through inhibitory cytokines, regulatory T cells (Tregs), and myeloid-derived suppressor cells (MDSCs); (2) exploitation of immune checkpoint pathways such as PD-1/PD-L1 and CTLA-4 to inhibit immune cell function; (3) remodeling of the tumor microenvironment via hypoxia, metabolic reprogramming, and stromal cell interactions to create an immunosuppressive niche; and (4) evasion of immune recognition through down-regulation of MHC class I molecules and immune-editing.

Tumor cells employ multiple mechanisms to suppress the immune system:
1.Secreting immunosuppressive factors (e.g., TGF-β, IL-10, VEGF) that inhibit T cell and NK cell function and promote Treg differentiation^[3].
2.Recruiting regulatory immune cells (e.g., Tregs, MDSCs) to suppress the activity of effector immune cells.
3.Undergoing metabolic reprogramming to produce high levels of metabolites such as lactate and ammonium, which acidify the tumor microenvironment, impair T cells, dendritic cells, and NK cells, and promote M2 macrophage polarization and Treg expansion.
4.Inducing mitochondrial damage and lysosomal dysfunction in T cells through the accumulation of lactate and ammonium, resulting in T cell death.

Tumors evade immune attack by overexpressing a variety of inhibitory immune checkpoint molecules. In addition to the well-known PD-L1/PD-1 and CTLA-4 pathways, tumors exploit other receptors, such as LAG-3, TIM-3, TIGIT, VISTA, and BTLA to suppress T cell and NK cell activity. Furthermore, CD47 engages SIRPα to inhibit macrophage phagocytosis, while co-stimulatory molecules such as OX40 and 4-1BB (CD137) exert anti-tumor effects by enhancing T cell responses. NK cell-associated checkpoints (e.g., KIR and NKG2A) are also exploited by tumors to evade innate immune surveillance^[4].

The TME is a complex ecosystem of tumor, stromal, and immune cells along with signaling molecules, actively shaping an immunosuppressive environment. Key mechanisms include: recruitment and polarization of immunosuppressive cells (e.g., M2-type TAMs, Tregs, and MDSCs); hypoxia-mediated stabilization of HIF-1α, which upregulates immune checkpoints like PD-L1 and impairs antigen presentation; metabolic reprogramming that accumulates lactate and limits nutrients, inhibiting T cell and NK cell function; secretion of chemokines (e.g., CCL2, CCL5, and CCL22) to recruit inhibitory cells; ECM remodeling and physical barriers by cancer-associated fibroblasts (CAFs) that restrict immune cell infiltration; and maintenance of immunosuppressive cytokine networks^[5].

Tumors disrupt antigen presentation and recognition to evade immune attack. Key mechanisms include: down-regulation of MHC class I molecules via mutational or epigenetic silencing, defects in the antigen processing machinery (APM), immune editing toward low-immunogenicity clones, dysregulation of co-stimulatory signals, and induction of T cell exhaustion characterized by high PD-1, TIM-3, and LAG-3 expression^[6].

Genetic and epigenetic alterations also contribute to tumor immune escape:
1.Oncogenes (e.g., KRAS, MYC) enhance PD-L1 or CD47 expression and induce immunosuppressive cytokines (TGF-β, IL-10), thereby inhibiting T cell and NK cell activity.
2.Loss of tumor suppressors (e.g., TP53, PTEN) diminishes antigen presentation through MHC class I down-regulation and activates PI3K/AKT signaling, promoting immune suppression.
3.Epigenetic modifications, including DNA methylation and histone alterations, silence genes involved in antigen processing and immune responses.
4.Non-coding RNAs (e.g., miR-21, miR-200) regulate checkpoint molecules and drive T cell exhaustion, contributing to therapeutic resistance.

Collectively, these changes reshape the tumor-immune interface and highlight potential targets for therapeutic intervention.

Current Therapeutic Strategies Targeting Cancer Immune Evasion

Building on our understanding of how tumors evade immunity, several therapeutic strategies have been developed to restore antitumor immune responses (Figure 2). These approaches target different mechanisms of immune escape.

Immune checkpoint inhibitors (ICIs) function by blocking inhibitory receptors on T cells (e.g., CTLA-4 and PD-1) or their ligands (e.g., PD-L1), thereby releasing the tumor-induced suppression of immune responses and restoring T cell-mediated antitumor activity. This approach has become a cornerstone of cancer therapy, with several agents approved for malignancies such as melanoma, non-small cell lung cancer, and hepatocellular carcinoma.

Cancer vaccines represent a therapeutic strategy designed to activate the immune system by presenting tumor antigens, enabling the recognition and elimination of existing tumors. The primary mechanism involves the presentation of tumor antigens (TAAs) or neoantigens by antigen-presenting cells (APCs) to cytotoxic T lymphocytes (CTLs), thereby eliciting a specific immune response and establishing immunological memory to prevent recurrence. Major vaccine types include peptide-based vaccines, dendritic cell (DC) vaccines, whole-cell vaccines, viral vector vaccines, and neoantigen-based vaccines.

Oncolytic viruses (OVs) represent a bifunctional anticancer modality that selectively infects and lyses tumor cells while simultaneously activating antitumor immunity. Their mechanisms include direct oncolysis, immune activation, reversal of immunosuppression in the tumor microenvironment, and mitigation of antigen escape. The approved agent T-VEC, which is used for melanoma, can induce both local and systemic immune responses. By combining direct tumor-killing effects with immunomodulatory mechanisms, OVs effectively address tumor immune evasion and serve as a pivotal strategy in cancer immunotherapy.

Adoptive cell therapy (ACT) is a precision immunotherapy approach that involves isolating, modifying, and expanding T cells from patients or donors, followed by reinfusion into the body to enhance antitumor immunity. This strategy directly counters tumor immune escape. Major modalities include CAR-T cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, and T cell receptor (TCR) therapy.

Epigenetic regulation is emerging as a promising strategy to overcome tumor immune evasion by modulating gene expression without altering the DNA sequence. Key mechanisms include restoring antigen presentation, regulating immune checkpoint molecules, and reprogramming the TME. Several epigenetic drugs, such as the DNA demethylating agent Azacitidine and histone deacetylase (HDAC) inhibitors, have been approved for the treatment of certain hematologic malignancies and solid tumors. Furthermore, combination strategies—including with PD-1/PD-L1 inhibitors, chemotherapy, or radiotherapy—can help overcome monotherapy resistance and enhance therapeutic efficacy.

In addition to established strategies, several innovative approaches are being developed to overcome tumor immune evasion:
1. Bispecific antibodies: These molecules simultaneously engage tumor-associated antigens and immune cell receptors, thereby directing T cell or NK cell–mediated cytotoxicity toward tumor cells.
2. Nanotechnology-driven immunotherapies: By enabling precise delivery of immunomodulatory agents, these approaches enhance drug stability and targeting specificity while minimizing off-target toxicity within the tumor microenvironment.
3. cGAS–STING pathway activation: Activation of this pathway restores innate immune sensing of tumor-derived DNA, induces type I interferon production, and promotes antigen presentation, ultimately enhancing adaptive immune responses.

These emerging modalities complement current immunotherapies and offer promising avenues to boost antitumor immunity and overcome therapeutic resistance.

Challenges and Future Directions in Overcoming Cancer Immune Evasion

Despite advances in immunotherapy, clinical outcomes remain highly variable, reflecting the complexity of tumor-immune interactions. Figure 4 summarizes the key clinical challenges and emerging strategies that are critical for guiding next-generation immunotherapy.

1.Tumor heterogeneity: spatial and temporal variations in genetic, epigenetic, and phenotypic profiles among tumor subclones drive diverse immune escape mechanisms and contribute to differential treatment responses and resistance.
2.Immune suppression within the TME: the TME is rich in immunosuppressive elements such as regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), inhibitory cytokines (e.g., TGF-β, IL-10), and checkpoint molecules (e.g., PD-L1), which collectively inhibit effector T cell function and promote immune tolerance.
3.Treatment resistance and relapse: both innate and adaptive resistance mechanisms—including loss of target antigens, upregulation of alternative immune checkpoints, T cell exhaustion, and metabolic dysregulation—limit durable responses to immunotherapies and often lead to disease recurrence.
4.Limited efficacy in “cold tumors”: immunologically “cold” tumors are characterized by poor T cell infiltration, defective antigen presentation, and a non-inflamed TME, resulting in minimal response to immune checkpoint inhibitors and other immunotherapies.
5.Off-target effects and toxicity: immunotherapy-related adverse events, such as cytokine release syndrome (CRS), immune-related adverse events (irAEs), neurotoxicity, and on-target/off-tumor effects of engineered T cells, pose significant safety challenges and limit therapeutic applicability.

1.Novel targets and combination therapies : developing therapies targeting emerging immune checkpoints (e.g., TIGIT, LAG-3, TIM-3, VISTA) and rational combination strategies—such as dual checkpoint blockade, immunotherapies with targeted agents, or epigenomic modulators—to overcome resistance and enhance antitumor immunity.
2.Personalized immunotherapy: leveraging multi-omics approaches (genomics, transcriptomics, proteomics, metabolomics) and AI-driven platforms to identify patient-specific neoantigens, predictive biomarkers, and immune signatures for tailored vaccines, cellular therapies, and treatment selection.
3.Biomarker development and monitoring: advancing dynamic biomarker platforms—including liquid biopsies, circulating tumor DNA (ctDNA), and immune cell profiling—to enable real-time assessment of treatment response, resistance mechanisms, and immune adaptation^[7].
4.Next-generation cell therapies: engineering enhanced CAR-T and CAR-NK cells with improved safety profiles, resistance to TME suppression, dual-targeting capabilities, and inducible control mechanisms to enhance efficacy and reduce toxicity.
5.Strategies to overcome “cold” tumors: utilizing oncolytic viruses, STING agonists, CD40 agonists, ECM-modifying agents, and metabolic interventions to reprogram the TME, promote immune cell infiltration, and convert immunologically “cold” tumors into “hot” ones.

Collectively, addressing these challenges will be key to achieving durable, precise, and widely effective cancer immunotherapy.

Cancer immune evasion is complex and multifaceted, posing a central challenge to effective therapy. Current strategies—including immune checkpoint inhibitors, CAR-T cell therapy, cancer vaccines, oncolytic viruses, and bispecific antibodies—have shown promise in counteracting immune resistance. Nevertheless, obstacles such as treatment resistance, limited predictive biomarkers, and the need for personalized therapeutic design persist. Future efforts should leverage multi-omics technologies (e.g., genomics, proteomics, metabolomics) and emerging modalities such as nanotechnology to enhance mechanistic understanding, guide the development of novel therapies, and ultimately enable more durable and individualized cancer treatment.

Note: MCE can provide products for research use only. We do not sell to patients.